Cecilia Brown

DocwireNews

The US Food and Drug Administration (FDA) has approved Optune Lua, a wearable treatment that delivers Tumor Treating Fields (TTFields) for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, according to an announcement from Novocure. The approval is for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) who have progressed on or after a platinum-based regimen.Optune Lua, which is the &ldquo;first treatment of its kind for metastatic NSCLC&rdquo; is a portable device that produces alternating electric fields known as <a href="https://www.docwirenews.com/post/minesh-mehta-md-discusses-the-metis-study-of-tumor-treating-fields-in-nsclc-with-brain-metastases" target="_blank" rel="noopener">TTFields</a> and delivers them through non-invasive, wearable arrays. TTFields &ldquo;exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death,&rdquo; officials explained in the announcement.&ldquo;Novocure is committed to extending survival in some of the most aggressive and difficult-to-treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with metastatic NSCLC who have progressed while on or after platinum-based chemotherapy,&rdquo; Novocure CEO Asaf Danziger said in a statement. &ldquo;We are grateful to the patients, caregivers, investigators and healthcare providers who supported the clinical trials that led to this approval.&rdquo;The device was evaluated in the <a href="https://www.docwirenews.com/post/phase-3-lunar-clinical-trial-results-to-be-presented-at-wclc-2024" target="_blank" rel="noopener">pivotal phase 3 LUNAR trial</a>, a prospective, randomized, open-label, multicenter study that compared the use of Optune Lua concurrent with PD-1/PD-L1 inhibitors (n=145) or docetaxel to PD-1/PD-L1 inhibitors or docetaxel alone (n=146) for patients with metastatic NSCLC who progressed during or after platinum-based therapy.The <a href="https://www.docwirenews.com/post/phase-3-lunar-trial-dr-rolfo-discusses-new-analysis-at-iaslc-2024-world-conference-on-lung-cancer" target="_blank" rel="noopener">LUNAR trial</a> met its primary endpoint by &ldquo;demonstrating a statistically significant and clinically meaningful&rdquo; extension of median overall survival (OS) by 3.3 months in patients who received concurrent treatment with Optune Lua and a PD-1/PD-L1 inhibitor or docetaxel (P=0.04).The median OS was 13.2 months (95% CI, 10.3 to 15.5 months) in patients who received the concurrent treatment with Optune Lua and a PD-1/PD-L1 inhibitor or docetaxel compared to a median OS of 9.9 months (95% CI, 8.2 to 12.2 months) in those who received a PD-1/PD-L1 inhibitor or docetaxel.Ticiana Leal, MD, Associate Professor and Director of the Thoracic Oncology Program at the Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia, and primary investigator of the LUNAR study, weighed in on the significance of the approval.&ldquo;There have been a number of important advances in first-line treatment for NSCLC, but this is an aggressive disease, and most patients will develop progression, with limited effective treatment options in second line and beyond,&rdquo; Dr. Leal said in a statement. &ldquo;The overall survival results we observed with Optune Lua in the LUNAR study mark the first substantial improvement in more than 8 years in this patient population which, when combined with Optune Lua&rsquo;s lack of systemic toxicity, make this a compelling development for many patients and their physicians who need better treatment options for this advanced disease.&rdquo;Device-related adverse events (AEs) occurred in 63.1% of patients (n=89). The AEs were skin-related disorders under the transducer arrays and the &ldquo;majority of these events were low grade&rdquo; AEs of grade 1 or 2, with only 4% (n=6) experiencing grade 3 skin toxicity requiring a break from treatment, officials said in the announcement. There were no grade 4 or grade 5 toxicities related to Optune Lua and no device-related AEs that caused death.GO2 for Lung Cancer Chief Patient Officer Danielle Hicks also shared her thoughts on the approval in a statement. &ldquo;We are excited patients with metastatic NSCLC have more options, which they urgently need,&rdquo; Hicks said. &ldquo;The fight against lung cancer is always evolving, and the number of people affected by this disease is underappreciated. That is why Novocure&rsquo;s commitment to advancing treatment is exciting for the whole lung cancer community.&rdquo;Source: <a href="https://www.novocure.com/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer/">Novocure</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

FDA Approves Wearable TTFields Treatment for Patients With Metastatic NSCLC

Non-Small Cell Lung Cancer

The US Food and Drug Administration (FDA) approved Optune Lua, a wearable treatment that delivers Tumor Treating Fields (TTFields) for concurrent use with PD-1/PD-L1 inhibitors.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe